Berenberg analysts adjusted their stance on Imerys (EPA:IMTP) (NK:FP) (OTC: IMYSF), downgrading the stock from Buy to Hold and significantly lowering the price target to €32.00 from the previous ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...

An OB/GYN was terse in her feedback, saying she needed an answer to inquiries from patients on whether their ovarian cancer ...

Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Key Takeaways The Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.

The U.S. Food and Drug Administration (FDA) has been playing catch-up on three long-delayed proposed rules required under the Modernization ...

Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from the same time last year.

Brown Rudnick LLP and Paul Hastings LLP can’t represent a talc claimants’ committee for Johnson & Johnson’s bankrupt ...

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

Mandatory testing of talc-containing cosmetic products is coming. At the end of December, the Food and Drug Administration ...